Market News Video
MNV MNV The 10 Most Popular Large-Caps in ETFs
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

March 23rd Options Now Available For Acadia Pharmaceuticals (ACAD)
Thursday, February 1, 11:32 AM ET, by Market News Video Staff

Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the March ...

CRL Crosses Below Key Moving Average Level
Friday, February 2, 4:08 PM ET, by Market News Video Staff

In trading on Friday, shares of Charles River Laboratories International Inc. (CRL) crossed below their ...

Investors Grab XON Even Lower Than Its Secondary Stock Offering
Monday, February 5, 11:10 AM ET, by Market News Video Staff

Looking back to 19 days ago, Intrexon Corp (XON) priced a 6,000,000 share secondary stock ...

Alkermes Breaks Below 200-Day Moving Average - Notable for ALKS
Tuesday, February 6, 2:15 PM ET, by Market News Video Staff

In trading on Tuesday, shares of Alkermes plc (ALKS) crossed below their 200 day moving ...

Noteworthy Tuesday Option Activity: TSLA, HD, ACAD
Tuesday, February 6, 3:21 PM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD

By Market News Video Staff, Wednesday, January 4, 11:54 AM ET
Play Video: Learn About The 200 DMA

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:

Acadia Pharmaceuticals Inc 200 Day Moving Average Chart

Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point that compares with a last trade of $31.24.

Special Offer: Join the income investing conversation on with a special Seven Days for Seven Dollars invitation.

According to the ETF Finder at ETF Channel, ACAD makes up 3.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF (AMEX:FBT) which is trading up by about 2.6% on the day Wednesday.

See what other ETFs contain ACAD
See what other stocks are held by FBT

This Article's Word Cloud:   ACAD   AMEX   Above   Acadia   According   Arca   Average   Biotechnology   Channel   Crossing   Days   Dollars   ETFs   Finder   First   Fund   Index   Join   Looking   Moving   NYSE   Offer   Pharmaceuticals   Seven   Special   Start   Stocks   Their   Trust   ValueForum   Wednesday   about   above   average   below   changing   chart   compares   contain   conversation   high   moving   other   point   share   shares   trading   week   what   with
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Chart Zero Stock Market Game Stock Market Definitions

Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD | Market News Video | Copyright © 2008 - 2018, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.